Lexaria Bioscience Corp. Secures $5.9 Million in Warrant Exercise

Kelowna, British Columbia — September 8, 2026 — Leads & Copy — Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced Tuesday it has entered into definitive agreements to immediately exercise certain outstanding warrants for an aggregate of 453,969 shares of the Company's common stock. The warrants, originally issued on various dates in 2024 and 2025 with original exercise prices ranging from $17.85 to $45.90 per share, will be exercised at a reduced price of $12.92 per share.

The closing of this warrant exercise transaction is anticipated to occur on or about September 9, 2026, contingent upon the satisfaction of standard closing conditions. H.C. Wainwright & Co. is serving as the exclusive placement agent for this offering.

The shares of common stock that will be issued upon the exercise of these warrants are registered under effective registration statements with the Securities and Exchange Commission (SEC), including Forms S-1 and S-3 with file numbers 333-277863, 333-283484, 333-290862, and 333-292469.

In exchange for the immediate cash exercise of the warrants, Lexaria Bioscience Corp. will issue new unregistered Series A warrants to purchase up to 453,969 shares of common stock and short-term Series B warrants to purchase up to 453,969 shares of common stock. The Series A Warrants will have an exercise price of $12.67 per share, will be immediately exercisable, and will expire five years from the effective date of the Resale Registration Statement. Similarly, the Series B Warrants will also have an exercise price of $12.67 per share, will be immediately exercisable, and will expire eighteen months from the effective date of the Resale Registration Statement.

The Company anticipates gross proceeds of approximately $5.9 million from this warrant exercise, before accounting for placement agent fees and other offering expenses. These net proceeds are intended to be used for working capital and general corporate purposes.

"We are extremely pleased for the potential $5.9 million in gross cash proceeds from the exercise of warrants," stated Rich Christopher, CEO of Lexaria. "The potential proceeds from this transaction, in combination with the $2.6 million tax rebate that we recently received from the Australian Tax Office, may be utilized to fund our operations and research and development programs in 2027."

The newly issued warrants and the shares of common stock issuable upon their exercise have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws. Consequently, these securities may only be offered or sold in the United States pursuant to an effective registration statement or an applicable exemption from registration requirements. Lexaria has committed to filing a resale registration statement with the SEC as soon as practicable for the shares underlying the new warrants.

Lexaria Bioscience Corp. is the developer of DehydraTECH™, a patented oral drug delivery formulation and processing platform technology designed to enhance the way various drugs enter the bloodstream. The technology has demonstrated the ability to increase bio-absorption, reduce side-effects, and improve the delivery of certain drugs across the blood-brain barrier. The company operates a licensed in-house research laboratory and possesses a portfolio of 66 granted patents, with additional applications pending globally.

Source: Lexaria Bioscience Corp.